MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer
K. C. Murphy, K. D. DeMarco, L. Zhou, Y. Lopez-Diaz, Y.-j. Ho, J. Li, S. Bai, K. Simin, L. J. Zhu, A. M. Mercurio, M. Ruscetti
This study shows that MYC and p53 alterations in prostate cancer cooperate via VEGF signaling to suppress T cell activity and immunotherapy responses, and that targeting VEGFR2 can enhance immunotherapy efficacy.
bioRxiv · Jul 24, 2024Cancer Biology